WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/016214    International Application No.:    PCT/US2006/029127
Publication Date: 08.02.2007 International Filing Date: 26.07.2006
A01N 33/18 (2006.01), A01N 33/24 (2006.01), A61K 31/045 (2006.01)
Applicants: CARITAS ST. ELIZABETH'S MEDICAL CENTER [US/US]; 736 Cambridge Street, Boston, MA 02135 (US) (For All Designated States Except US).
OXENKRUG, Gregory [US/US]; (US) (For US Only).
JABER, Bertrand, L. [LB/US]; (US) (For US Only).
PERIANAYAGAM, Mary, C. [IN/US]; (US) (For US Only)
Inventors: OXENKRUG, Gregory; (US).
JABER, Bertrand, L.; (US).
Agent: RESNICK, David, S.; NIXON PEABODY LLP, 100 Summer Street, Boston, MA 02110-2131 (US)
Priority Data:
60/704,793 02.08.2005 US
Abstract: front page image
(EN)The present invention encompasses methods for inhibiting TNF-alpha expression with N- substituted dopamine derivatives. In this method a cell is administered a pharmaceutically effective amount of N-acetyl dopamine derivatives or N-alkyldopamine derivatives and a pharmaceutically acceptable carrier for treating a cell, preferably in an animal or human suffering from overexpression or abundant TNF-alpha. The N-acetyldopamine derivative or N- alkyldopamine derivatives may be administered alone or in combination with N-acetylserotonin (NAS) or other compound to inhibit TNF-alpha expression. Also disclosed is a method of treating a TNF-alpha related disease and/or disorder using such a compound.
(FR)L'invention concerne des méthodes permettant d'inhiber l'expression deTNF-alpha à l'aide de dérivés de dopamine à substitution N. Cette méthode consiste à administrer, de préférence, à un animal ou un humain souffrant de surexpression ou d'excès de TNF-alpha, une quantité pharmaceutiquement efficace de dérivés de N-acétyldopamine ou de dérivés de N-alkyldopamine et un excipient pharmaceutiquement acceptable permettant de traiter une cellule. Les dérivés N-acétyldopamine ou N-alkyldopamine peuvent s'administrer seuls ou en combinaison avec N-acétylsérotonine (NAS) ou un autre composé afin d'inhiber l'expression deTNF-alpha. L'invention concerne également une méthode permettant de traiter une maladie et/ou un trouble associé à TNF-alpha à l'aide dudit composé.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)